Open in Screener

KYTX

Kyverna Therapeutics Inc

Sep 16 • 10:09AM ET

3.93

+0.02 0.64 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AMGN VRTX JNJ REGN GILD BMRN PFE BMY NVAX

| Held by: VTI VXF IBB SCHA IWC AVSC SCHB MSSM IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-3.67	Insider Own	50.70%	Shs Outstand	43.24M	Perf Week	-4.02%
Market Cap	170.17M	Forward P/E	-	EPS next Y	-3.59	Insider Trans	0.00%	Shs Float	21.32M	Perf Month	12.11%
Enterprise Value	-35.59M	PEG	-	EPS next Q	-0.95	Inst Own	25.06%	Short Float	6.32%	Perf Quarter	24.92%
Income	-158.70M	P/S	-	EPS this Y	-15.44%	Inst Trans	-18.74%	Short Ratio	3.43	Perf Half Y	54.92%
Sales	0.00M	P/B	0.92	EPS next Y	6.73%	ROA	-53.83%	Short Interest	1.35M	Perf YTD	5.21%
Book/sh	4.26	P/C	0.80	EPS next 5Y	-3.60%	ROE	-61.29%	52W High	7.35 -46.46%	Perf Year	-43.71%
Cash/sh	4.89	P/FCF	-	EPS past 3/5Y	-75.88% -	ROIC	-84.99%	52W Low	1.78 121.07%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.89% 8.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-39.69%	Oper. Margin	-	ATR (14)	0.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.39	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.47	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.39	EPS Q/Q	-45.82%	SMA20	4.01%	Beta	3.15	Target Price	18.20
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	5.72%	Rel Volume	0.20	Prev Close	3.91
Employees	112	LT Debt/Eq	0.01	Earnings	Aug 12 AMC	SMA200	23.68%	Avg Volume	393.12K	Price	3.93
IPO	Feb 08, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.08% -	Trades		Volume	11,182	Change	0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Sep-15-25 01:02PM	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (GlobeNewswire)
Aug-28-25 08:00AM	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event (GlobeNewswire)
Aug-25-25 04:02PM	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire) +14.90%
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
10:23AM	Loading…
Jul-29-25 10:23AM	Kyverna Appoints New CFO to Guide Next Growth Phase (Insider Monkey) -11.09%
08:30AM	Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise (PR Newswire)
Jun-30-25 09:00AM	Kyverna Therapeutics Announces Appointment of New Chief Financial Officer (PR Newswire) -6.40%
May-28-25 04:02PM	Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
May-13-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM	Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM	Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM	Loading…
08:32AM	Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM	Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-03-25 04:05PM	Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference (PR Newswire) -8.80%
Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
10:01AM	Loading…
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Open in Screener

ANNX

Annexon Inc

Sep 16 • 10:09AM ET

2.54

+0.05 2.05 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX RARE CRSP NTLA EDIT ALLO BLUE FOLD MYO SGMO

| Held by: VTI IWM IWN VXF IBB SCHA VTWO DFAC IWC AVSC

Index	RUT	P/E	-	EPS (ttm)	-1.29	Insider Own	12.92%	Shs Outstand	109.83M	Perf Week	19.86%
Market Cap	279.22M	Forward P/E	-	EPS next Y	-1.36	Insider Trans	0.07%	Shs Float	95.69M	Perf Month	4.14%
Enterprise Value	79.83M	PEG	-	EPS next Q	-0.34	Inst Own	85.61%	Short Float	10.59%	Perf Quarter	4.14%
Income	-188.78M	P/S	-	EPS this Y	-37.13%	Inst Trans	0.09%	Short Ratio	6.48	Perf Half Y	-7.60%
Sales	0.00M	P/B	1.40	EPS next Y	1.53%	ROA	-55.74%	Short Interest	10.14M	Perf YTD	-50.47%
Book/sh	1.81	P/C	1.23	EPS next 5Y	7.80%	ROE	-66.75%	52W High	7.85 -67.63%	Perf Year	-62.24%
Cash/sh	2.07	P/FCF	-	EPS past 3/5Y	33.38% -0.09%	ROIC	-84.30%	52W Low	1.28 97.74%	Perf 3Y	-60.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.37% 7.45%	Perf 5Y	-90.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.57%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.67	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.17	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.67	EPS Q/Q	-51.16%	SMA20	14.30%	Beta	1.30	Target Price	11.60
Payout	-	Debt/Eq	0.14	Sales Q/Q	-	SMA50	6.92%	Rel Volume	0.96	Prev Close	2.49
Employees	100	LT Debt/Eq	0.13	Earnings	Aug 14 AMC	SMA200	-11.70%	Avg Volume	1.56M	Price	2.54
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.21% -	Trades		Volume	218,543	Change	2.05%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Aug-27-25 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.81%
Aug-14-25 04:05PM	Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -8.46%
Aug-11-25 07:29AM	Annexon announces EMA selection of vonaprument for PDC pilot participation (Pharmaceutical Business Review)
Aug-07-25 04:30PM	Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy (GlobeNewswire)
07:00AM	Loading…
Jul-24-25 07:00AM	Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
Jun-18-25 04:05PM	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) (GlobeNewswire)
May-29-25 04:05PM	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.39% -6.42%
May-19-25 04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-16-25 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
May-12-25 08:00AM	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +10.62%
May-09-25 05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire) -5.88%
05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire)
08:00AM	Loading…
May-07-25 08:00AM	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress (GlobeNewswire)
Apr-16-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-15-25 07:12AM	Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (Seeking Alpha)
Apr-10-25 09:24AM	Why Annexon Inc. (ANNX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 03:20PM	Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder (Benzinga) -7.79%
Apr-08-25 04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -5.52%
04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Apr-03-25 06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barre Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -6.63% -7.65%
06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77% -9.09%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-03-25 08:00AM	Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -9.47%
Feb-26-25 04:05PM	Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)
04:45AM	Annexons ANX005 offers improvement in Phase III GBS trial (Clinical Trials Arena)
Jun-04-24 05:06PM	Annexon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +30.79%
12:06PM	Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study (Benzinga)
08:46AM	Annexon shares leap as Guillain-Barr drug reduces disability in phase 3 (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barre Syndrome (GlobeNewswire)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome (GlobeNewswire)
Jun-03-24 04:30PM	Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data (GlobeNewswire) -5.18%
May-20-24 09:35AM	Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.08%
May-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 02:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones (GlobeNewswire)
May-09-24 08:00AM	Annexon Biosciences to Present at the Bank of America Health Care Conference (GlobeNewswire)
May-07-24 12:30PM	Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting (GlobeNewswire)
May-01-24 10:15AM	Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-25-24 09:35AM	Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) (Zacks)
Apr-17-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks) -10.36%
Apr-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.89%
09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 06:15PM	Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Apr-03-24 08:00AM	Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 12:00PM	What Makes Annexon (ANNX) a New Buy Stock (Zacks) -7.53%
09:55AM	Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade (Zacks)
Mar-28-24 05:31AM	Annexon Inc (ANNX) Reports Year-End Financials, Aligns with Analyst Projections (GuruFocus.com) -8.19%
Mar-26-24 08:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q4 2023 (InvestorPlace) +13.52%
04:05PM	Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones (GlobeNewswire)
Mar-18-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.98%
Mar-14-24 08:40AM	Why Annexon (ANNX) Might Surprise This Earnings Season (Zacks)
Mar-12-24 02:51PM	J.P. Morgan Predicts up to 140% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-24 08:00AM	Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-21-24 08:00AM	Annexon to Host Virtual R&D Day on Guillain-Barr Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach (GlobeNewswire) -5.39%
Feb-20-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:10PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Annexon Inc (GuruFocus.com) -7.73%
Jan-18-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.87%

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carson William H.	Director	Sep 02 '25	Buy	2.09	4,115	8,600	37,945	Sep 04 04:30 PM
Carson William H.	Director	Jul 30 '25	Buy	2.43	4,115	9,999	33,830	Aug 01 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jul 14 '25	Sale	2.58	1,116	2,879	105,084	Jul 16 04:20 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Jul 14 '25	Sale	2.58	1,117	2,882	121,616	Jul 16 04:20 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Jul 14 '25	Sale	2.61	853	2,226	130,689	Jul 16 04:20 PM
Yednock Ted	Officer	Jul 14 '25	Proposed Sale	2.58	1,116	2,881		Jul 14 03:51 PM
Overdorf Michael	Officer	Jul 14 '25	Proposed Sale	2.61	853	2,226		Jul 14 03:26 PM
Lew Jennifer	Officer	Jul 14 '25	Proposed Sale	2.58	1,117	2,881		Jul 14 03:17 PM
Carson William H.	Director	Jun 30 '25	Buy	2.46	4,115	10,123	29,715	Jul 01 04:55 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	2.96	5,521	16,342	33,479	Feb 20 04:54 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	2.97	5,515	16,380	83,814	Feb 20 04:52 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '25	Sale	2.91	8,345	24,284	61,237	Feb 20 04:51 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '25	Sale	2.95	6,618	19,523	86,579	Feb 20 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '25	Sale	2.92	6,912	20,183	77,770	Feb 20 04:48 PM
Love Douglas	PRESIDENT AND CEO	Feb 13 '25	Sale	2.95	5,021	14,812	351,554	Feb 18 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 13 '25	Sale	2.98	1,786	5,322	84,682	Feb 18 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 13 '25	Sale	2.99	1,425	4,261	93,197	Feb 18 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 13 '25	Sale	2.99	1,783	5,331	69,582	Feb 18 04:30 PM
Yednock Ted	Officer	Feb 18 '25	Proposed Sale	2.91	8,345	24,321		Feb 18 03:21 PM
Lew Jennifer	Officer	Feb 18 '25	Proposed Sale	2.92	8,338	24,319		Feb 18 03:15 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '25	Proposed Sale	2.97	5,515	16,359		Feb 18 03:15 PM
Dananberg Jamie	Officer	Feb 18 '25	Proposed Sale	2.96	5,521	16,359		Feb 18 03:13 PM
Overdorf Michael	Officer	Feb 18 '25	Proposed Sale	2.95	6,618	19,514		Feb 18 03:11 PM
Yednock Ted	Officer	Feb 13 '25	Proposed Sale	2.98	1,783	5,316		Feb 13 03:18 PM
Love Douglas	Officer	Feb 13 '25	Proposed Sale	2.95	5,021	14,799		Feb 13 03:13 PM
Lew Jennifer	Officer	Feb 13 '25	Proposed Sale	2.98	1,786	5,314		Feb 13 03:12 PM
Overdorf Michael	Officer	Feb 13 '25	Proposed Sale	2.99	1,425	4,265		Feb 13 03:06 PM
Love Douglas	PRESIDENT AND CEO	Jan 06 '25	Option Exercise	1.41	37,994	53,556	356,575	Jan 08 05:58 PM
Carson William H.	Director	Dec 02 '24	Buy	5.33	3,200	17,056	25,600	Dec 04 06:12 PM
Love Douglas	PRESIDENT AND CEO	Oct 30 '24	Option Exercise	1.85	114,449	211,742	310,570	Nov 01 04:15 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Oct 15 '24	Option Exercise	1.85	5,408	10,005	76,773	Oct 17 05:09 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Oct 15 '24	Sale	7.41	5,408	40,073	71,365	Oct 17 05:09 PM
Yednock Ted	Officer	Oct 15 '24	Proposed Sale	7.41	5,408	40,073		Oct 15 02:03 PM
Carson William H.	Director	Oct 01 '24	Buy	5.97	3,200	19,104	22,400	Oct 02 04:15 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 19 '24	Sale	7.10	4,500	31,950	0	Sep 20 04:30 PM
Yednock Ted	Officer	Sep 19 '24	Proposed Sale	7.10	4,500	31,950		Sep 19 12:32 PM

KYTX

Kyverna Therapeutics Inc

ANNX

Annexon Inc

Upgrade your FINVIZ experience